






FIG. 2















FIG. 7B










FIG. 7E


FIG. 7F


















FIG. 11B





18/35

FIG. 11C-2 FIG. 11C-1


FIG. 11C-3 FIG. 11C-4


FIG. 11D







Time After Administration (minutes)











Time of Administration


Relative Time to Clot Formation (experimental/vehicle)







Factor IXai Dose (µg/kg)

FIG. 16A







111_{In-PLT} deposition (ratio of lung radioactivity to blood activity)




29/35




30/35





32/35



33/35

34/35




FIG. 22

